---
id: sgobs.healthcare.hsa-post-marketing-vigilance-guidance-2026.revision
kind: observation
title: "HSA上市后警戒指南第 6 版"
url: https://ik.sg/zh/knowledge/observation/sgobs.healthcare.hsa-post-marketing-vigilance-guidance-2026.revision
language: zh-Hans
evidence_status: final
collection_as_of: 2026-11-22
---

# HSA上市后警戒指南第 6 版

## 记录详情

- **分母口径:** Guidance scope; not a marketing-authorisation decision and not a declaration that every adverse event is reportable
- **地理范围:** [新加坡](https://ik.sg/zh/knowledge/geography/sg.geo.country.singapore)
- **数值类型:** observation
- **指标:** revision (`sgmetric.healthcare.hsa-post-marketing-vigilance-guidance-2026.revision`)
- **适用人群:** Companies responsible for post-marketing surveillance of therapeutic products and CTGTP in Singapore
- **发布日期:** 2026-04-01
- **统计期间:** Version 6 uploaded 1 April 2026
- **来源版本:** HSA Guidance Version 6
- **状态:** final
- **单位:** guidance revision
- **数值:** HSA uploaded Version 6 of the post-marketing vigilance guidance on 1 April 2026, revising scope, contact requirements, serious-adverse-event criteria, identifiable-patient examples, literature reports, lack-of-efficacy reports, clinical safety study reports and eCTD submission references

## 资料来源

- [https://isomer-user-content.by.gov.sg/409/a6db49dc-ed7f-4e44-93ad-7fb906e7d2f8/Guidance%20for%20Industry_Post-marketing%20Vigilance%20Requirements%20for%20Therapeutic%20Products%20and%20CTGTP_V.pdf](https://isomer-user-content.by.gov.sg/409/a6db49dc-ed7f-4e44-93ad-7fb906e7d2f8/Guidance%20for%20Industry_Post-marketing%20Vigilance%20Requirements%20for%20Therapeutic%20Products%20and%20CTGTP_V.pdf) — 访问日期 2026-09-02

## 探索关联

- 主题: [HSA 上市后监测指南 2026 年](https://ik.sg/zh/knowledge/topic/sgtopic.healthcare.hsa-post-marketing-vigilance-guidance-2026)
- 地点: [新加坡](https://ik.sg/zh/knowledge/geography/sg.geo.country.singapore)

日期表示本记录的统计期间与适用范围。核验日期并不代表规则目前已经生效。 知识库持续扩充中。发布数量表示现有内容，并不代表已覆盖新加坡的全部知识。
